Vesal­ius bags €65M biotech fund while No­var­tis vet Gui­di can­vas­es for a €50M gam­ble on Ital­ian sci­en­tists

The Lux­em­bourg-based biotech ven­ture firm Vesal­ius Bio­cap­i­tal has raised more than €65 mil­lion for its third fund, which will re­main open in search of ad­di­tion­al cash.

Vesal­ius has been broad­en­ing its hori­zons be­yond late-stage Eu­ro­pean in­vest­ments in drug de­vel­op­ment, medtech, di­ag­nos­tics and eHealth/mHealth, open­ing an of­fice in Boston to see if it can get in on some of the US syn­di­cates.

Vesal­ius has en­joyed a few sig­nif­i­cant ex­its re­cent­ly, in­clud­ing Oge­da (ac­quired by Astel­las for €800 mil­lion), Ac­ti­vaero (sold to Vec­tura for €130 mil­lion), Genky­otex (re­verse merg­er on Eu­ronext) and Fovea (ac­quired by Sanofi for €370 mil­lion).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.